

## DAFTAR PUSTAKA

- Andersen, N. F. *et al.*, 2014. Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival. *European Journal of Haematology*, 94(1), pp. 60–66. doi: 10.1111/ejh.12401.
- Anggorowati, N. *et al.*, 2018. Upregulation of endothelin-1/endothelin a receptor expression correlates with heparanase expression in ovarian carcinoma. *Iranian Journal of Medical Sciences*, 43(3), pp. 286–295.
- Bray, F. *et al.*, 2018. Global Cancer Statistics 2018 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *Ca Cancer J Clin.* doi: 10.3322/caac.21492.
- Carmeliet, P. and Jain, R. K., 2000. Angiogenesis in cancer and other diseases. *Nature*, 407, pp. 249–257.
- Chanock, S., 2001. Candidate genes and single nucleotide polymorphisms (SNPs) in the study of human disease. *Disease Markers*, 17, pp. 89–98.
- Cobb, L. P. *et al.*, 2015. Adenocarcinoma of Mullerian origin : review of pathogenesis, molecular biology, and emerging treatment paradigms. *Gynecologic Oncology Research and Practice*, pp. 1–16. doi: 10.1186/s40661-015-0008-z.
- Conklin, C. M. and Gilks, C. B., 2013. Differential diagnosis and clinical relevance of ovarian carcinoma subtypes. *Expert Rev. Obstet. Gynecol*, 8(1), pp. 1–16.
- Ezzati, M. *et al.*, 2014. Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma. *International Scholarly Research Notices*, 2014, pp. 1–10. doi: 10.1155/2014/953509.
- Ferlay, J. *et al.*, 2015. Cancer incidence and mortality worldwide : Sources, methods and major patterns in GLOBOCAN 2012. *International Journal of Cancer*, 136, pp. E359–E386. doi: 10.1002/ijc.29210.
- Ginath, S. *et al.*, 2001. Expression of heparanase, Mdm2, and erbB2 in ovarian cancer. *International Journal of Oncology*, (14), pp. 1133–1144.
- Horvath, L. E. *et al.*, 2013. The relationship between tumor size and stage in early versus advanced ovarian cancer. *Medical Hypotheses*, 80(5), pp. 684–687. doi: 10.1016/j.mehy.2013.01.027.
- Howlader, N. *et al.*, 2017. SEER Cancer Statistics Review 1975-2014 National Cancer Institute. Bethesda, MD.
- Huang, G. *et al.*, 2012. Allele Loss and Down-Regulation of Heparanase Gene Are Associated with the Progression and Poor Prognosis of Hepatocellular Carcinoma. *Plos One*, 7(8). doi: 10.1371/journal.pone.0044061.

- Jha, R. and Karki, S., 2008. Histological pattern of ovarian tumors and their age distribution. *Nepal Med Coll J*, 10(2), pp. 81–85.
- Khan, M. A. *et al.*, 2017. Frequency of Ovarian Tumors According to WHO Histological Classification and Their Association to Age at Diagnosis. *Annals*, 23(2).
- Khunamornpong, S. *et al.*, 2011. Mucinous Tumor of Low Malignant Potential (“Borderline” or “Atypical Proliferative” Tumor) of the Ovary: A Study of 171 Cases With the Assessment of Intraepithelial Carcinoma and Microinvasion. *International Journal of Gynecological Pathology*, (30), pp. 218–230. doi: 10.1097/PGP.0b013e3181fcf01a.
- Kodama, J. *et al.*, 2003. Heparanase messenger RNA expression in epithelial ovarian tumor. *International Journal of Molecular Medicine*, pp. 961–964.
- Kurman, R. J. *et al.*, 2014. *WHO Classification of Tumours of Female Reproductive Organs, International Agency for Research on Cancer (IARC), Lyon, France.*
- Kurman, R. J. and Shih, I., 2010. The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. *Am J Surg Pathol*, 34(3), pp. 433–443.
- Li, A. *et al.*, 2012. Polymorphisms and a Haplotype in Heparanase Gene Associations with the Progression and Prognosis of Gastric Cancer in a Northern Chinese Polymorphisms and a Haplotype in Heparanase Gene Associations with the Progression and Prognosis of Gastric Cancer. *Plos One*, 7(1). doi: 10.1371/journal.pone.0030277.
- Mabuchi, S., Sugiyama, T. and Kimura, T., 2016. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. *J Gynecol Oncol*, 27(3), pp. 1–14.
- Maniar, K. P. *et al.*, 2014. Evaluation of Microinvasion and Lymph Node Involvement in Ovarian Serous Borderline/Atypical Proliferative Serous Tumors A Morphologic and Immunohistochemical Analysis of 37 Cases. *Am J Surg Pathol*, 38(6), pp. 743–755.
- Minal, J. *et al.*, 2015. Grading ovarian serous carcinoma using a two tier system: Does it have prognostic significance? *International Journal of Biomedical and Advance Research*, 6(3), pp. 269–274. doi: 10.7439/ijbar.
- Okugawa, K. *et al.*, 2001. Relationship between age, histological type, and size of ovarian tumors. *International Journal of Gynecology & Obstetrics*, 74, pp. 45–50.

- Onal, Y. *et al.*, 2017. Assessment of Prognostic Factors in Epithelial Ovarian Cancer. *Eurasian Journal of Medicine and Oncology*, 1(2), pp. 61–68. doi: 10.14744/ejmo.2017.43531.
- Ostrovsky, O. *et al.*, 2007. Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. *Leukemia*, 21(11), pp. 2296–2303. doi: 10.1038/sj.leu.2404821.
- Ostrovsky, O. *et al.*, 2009. Inverse correlation between HPSE gene single nucleotide polymorphisms and heparanase expression: possibility of multiple levels of heparanase regulation. *Journal of Leukocyte Biology*, 86(2), pp. 445–455. doi: 10.1189/jlb.1208735.
- Ostrovsky, O. *et al.*, 2010. Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation : effect of discrepancy between recipients and donors. *Blood*, 115(11), pp. 2319–2329. doi: 10.1182/blood-2009-08-236455.
- Ostrovsky, O. *et al.*, 2018. Identification of strong intron enhancer in the heparanase gene : effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies. *Oncogenesis*. Springer US. doi: 10.1038/s41389-018-0060-8.
- Prat, J., 2012. Ovarian carcinomas : five distinct diseases with different origins, genetic alterations, and clinicopathological features. *Virchows Arch*, (460), pp. 237–249. doi: 10.1007/s00428-012-1203-5.
- Prat, J., 2015. FIGO ' s staging classification for cancer of the ovary, fallopian tube, and peritoneum : abridged republication. *Journal of Gynecologic Oncology*, 26(2), pp. 87–89.
- Przybycin, C. G. *et al.*, 2010. Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin ?, *Am J Surg Pathol*, 34(10), pp. 1407–1416.
- Ralph, S. *et al.*, 2007. Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma. *Cancer Science*, 98(6), pp. 844–849. doi: 10.1111/j.1349-7006.2007.00461.x.
- Razi, S. *et al.*, 2016. The incidence and mortality of ovarian cancer and their relationship with the Human Development Index in Asia. *Ecancer medical science*, 10(628), pp. 1–11. doi: 10.3332/ecancer.2016.628.
- Reid, B. M., Permuth, J. B. and Sellers, T. A., 2017. Epidemiology of ovarian cancer : a review, *Cancer Biology*. doi:10.20892/j.issn.2095-3941.2016.0084.
- Rodriguez, I. M. and Prat, J., 2002. Mucinous Tumors of the Ovary : A Clinicopathologic Analysis of 75 Borderline Tumors (of Intestinal Type) and Carcinomas. *The American Journal of Surgical Pathology*, 26(2), pp. 139–152.

- Salvador, S. *et al.*, 2009. The Fallopian Tube : Primary Site of Most Pelvic High-grade Serous Carcinomas. *International Journal of Gynecological Cancer*, 19(1), pp. 58–64. doi: 10.1111/IGC.0b013e318199009c.
- Sanderson, R. D. *et al.*, 2017. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. *Federation of European Biochemical Societies Journal*, 284(1), pp. 42–55. doi: 10.1111/febs.13932.
- Sarangan, A. and Andal, N., 2017. Clinicopathological and Histological Features of Ovarian Tumour- A Study. *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*, 16(9), pp. 56–60. doi: 10.9790/0853-1609095660.
- Secchi, M. F. *et al.*, 2015. Recent data concerning heparanase: Focus on fibrosis, inflammation and cancer. *Biomolecular Concepts*, 6(5–6), pp. 415–421. doi: 10.1515/bmc-2015-0021.
- Shih, I. and Kurman, R. J., 2014. Evaluation of Microinvasion and Lymph Node Involvement in Ovarian Serous Borderline/Atypical Proliferative Serous Tumors A Morphologic and Immunohistochemical Analysis of 37 Cases. *Am J Surg Pathol*, 38(6), pp. 743–755.
- Singh, N., McCluggage, W. G. and Gilks, C. B., 2017. High-grade serous carcinoma of tubo-ovarian origin: recent developments. *Histopathology*, 71(3), pp. 339–356. doi: 10.1111/his.13248.
- Soegaard, M. *et al.*, 2007. Different Risk Factor Profiles for Mucinous and Nonmucinous Ovarian Cancer : Results from the Danish MALOVA Study. *Cancer Epidemiol Biomarkers Prev*, 16(June), pp. 1160–1167. doi: 10.1158/1055-9965.EPI-07-0089.
- Soslow, R. and Tornos, C., 2011. *Diagnostic Pathology of Ovarian Tumors*.
- Sun, X. *et al.*, 2017. Elevated heparanase expression is associated with poor prognosis in breast cancer : a study based on systematic review and TCGA data. *Oncotarget*, 8(26), pp. 43521–43535.
- Tian, Q. *et al.*, 2016. Early stage primary ovarian mucinous carcinoma : Outcome-based clinicopathological study in comparison with serous carcinoma. *Journal of International Medical Research*, 44(2), pp. 357–366. doi: 10.1177/0300060515597930.
- Vlodavsky, I. *et al.*, 2016. Heparanase: From basic research to therapeutic applications in cancer and inflammation. *Drug Resistance Updates*. Elsevier Ltd. doi: 10.1016/j.drug.2016.10.001.
- Vlodavsky, I. *et al.*, 2017. Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer Progression. *Trends in Biochemical Sciences*. Elsevier Ltd, xx, pp. 1–14. doi: 10.1016/j.tibs.2017.10.007.

- Wang, M. *et al.*, 2010. Notch1 expression correlates with tumor differentiation status in ovarian carcinoma. *Med Oncol*, (27), pp. 1329–1335. doi: 10.1007/s12032-009-9384-8.
- Wang, Z. *et al.*, 2005. Positive association of heparanase expression with tumor invasion and lymphatic metastasis in gastric carcinoma. *Modern pathology*, pp. 205–211. doi: 10.1038/modpathol.3800282.
- Yu, L. *et al.*, 2017. Association of polymorphisms in the heparanase gene (HPSE) with hepatocellular carcinoma in Chinese populations. *Genetics and Molecular Biology*, 40(4), pp. 743–750. doi: 10.1590/1678-4685-gmb-2014-0338.